ZA979327B
(en)
|
1996-10-18 |
1998-05-11 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
ATE369132T1
(de)
*
|
2002-10-17 |
2007-08-15 |
Teva Pharma |
Verfahren zur herstellung von losartan kaliumsalz mit verbesserten fliesseigenschaften
|
AU2003278422A1
(en)
*
|
2002-10-31 |
2004-05-25 |
Ranbaxy Laboratories Limited |
Amorphous form of losartan potassium
|
IL154370A0
(en)
*
|
2003-02-10 |
2003-09-17 |
Chemagis Ltd |
Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
|
ITMI20030328A1
(it)
*
|
2003-02-25 |
2004-08-26 |
Dinamite Dipharma S P A In Forma A Bbreviata Diph |
Polimorfi di losartan potassio e procedimento per la loro preparazione.
|
WO2004076443A1
(en)
*
|
2003-02-25 |
2004-09-10 |
Hetero Drugs Limited |
Amorphous form of losartan potassium
|
WO2004076442A1
(en)
*
|
2003-02-28 |
2004-09-10 |
Ranbaxy Laboratories Limited |
Polymorphs of losartan
|
US7345071B2
(en)
|
2003-05-07 |
2008-03-18 |
Ipca Laboratories Limited |
Process for the synthesis of Losartan potassium
|
PE20050374A1
(es)
|
2003-09-05 |
2005-05-30 |
Vertex Pharma |
Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
|
ITMI20032472A1
(it)
*
|
2003-12-16 |
2005-06-17 |
Dinamite Dipharma S P A In Forma A Bbreviata Diph |
Procedimento per la preparazione di losartan potassio cristallino
|
EP1709034A2
(en)
*
|
2004-01-06 |
2006-10-11 |
IPCA Laboratories Limited |
An improved process for the synthesis of losartan potassium
|
EP1713795A2
(en)
|
2004-02-11 |
2006-10-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
EP1729766A1
(en)
*
|
2004-03-01 |
2006-12-13 |
LEK Pharmaceuticals D.D. |
Pharmaceutical formulation
|
WO2005084669A1
(en)
*
|
2004-03-01 |
2005-09-15 |
Lek Pharmaceuticals D.D. |
Pharmaceutical composition
|
EP1742938A1
(en)
*
|
2004-05-05 |
2007-01-17 |
Teva Pharmaceutical Industries Ltd. |
Preparation of candesartan cilexetil in high purity
|
CN1988885A
(zh)
*
|
2004-06-08 |
2007-06-27 |
沃泰克斯药物股份有限公司 |
药物组合物
|
US7592459B2
(en)
|
2004-09-29 |
2009-09-22 |
Chemagis Ltd. |
Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
|
WO2006076097A2
(en)
*
|
2004-12-07 |
2006-07-20 |
Nektar Therapeutics |
Stable non-crystalline formulation comprising losartan
|
US20090076281A1
(en)
*
|
2005-05-05 |
2009-03-19 |
Medichem, S.A. |
Process for the preparation of losartan and its salts
|
RU2441020C2
(ru)
*
|
2005-08-02 |
2012-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы серинпротеазы
|
AR055395A1
(es)
*
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7964624B1
(en)
*
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
WO2007049292A1
(en)
*
|
2005-10-27 |
2007-05-03 |
Lupin Limited |
Pharmaceutical formulation of losartan
|
AU2006332726B2
(en)
|
2005-12-28 |
2012-12-13 |
Vertex Pharmaceuticals Incorporated. |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
WO2007098270A2
(en)
|
2006-02-27 |
2007-08-30 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
|
CA2646229A1
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
PT2114924E
(pt)
*
|
2007-02-27 |
2012-04-03 |
Vertex Pharma |
Co-cristais e composições farmacêuticas que compreendem os mesmos
|
EP2134717A2
(en)
*
|
2007-02-27 |
2009-12-23 |
Vertex Pharmceuticals Incorporated |
Inhibitors of serine proteases
|
MX2010002407A
(es)
*
|
2007-08-30 |
2010-03-26 |
Vertex Pharma |
Cocristales y composiciones farmaceuticas que los comprenden.
|
EP3842037A1
(en)
|
2008-08-13 |
2021-06-30 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
EP2413931B1
(en)
|
2009-01-23 |
2016-06-01 |
Hanmi Science Co., Ltd. |
Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
|
US20110098311A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorported |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
WO2011133953A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
EP2560651A1
(en)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
CA2796642A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US20110288122A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical Compositions and Administrations Thereof
|
RU2013113627A
(ru)
|
2010-08-27 |
2014-10-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтическая композиция и ее введения
|
WO2013067410A1
(en)
|
2011-11-02 |
2013-05-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating cftr mediated diseases
|
CN109966264A
(zh)
|
2012-02-27 |
2019-07-05 |
沃泰克斯药物股份有限公司 |
药物组合物及其施用
|
CA2874851A1
(en)
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cftr-mediated disorders
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
EP3789394A1
(en)
|
2012-06-19 |
2021-03-10 |
Intercept Pharmaceuticals, Inc. |
Crystalline forms c of obeticholic acid
|
SG10202012791TA
(en)
|
2013-11-15 |
2021-01-28 |
Akebia Therapeutics Inc |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
|
SI3925607T1
(sl)
|
2014-04-15 |
2023-10-30 |
Vertex Pharmaceuticals Incorporated |
Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
|
MA41051B1
(fr)
|
2014-10-06 |
2020-11-30 |
Vertex Pharma |
Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
|
JOP20190125B1
(ar)
|
2016-12-09 |
2022-03-14 |
Vertex Pharma |
مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|
US11253509B2
(en)
|
2017-06-08 |
2022-02-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
CA3068609A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
MA49631A
(fr)
|
2017-07-17 |
2020-05-27 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
CA3078893A1
(en)
|
2017-10-19 |
2019-04-25 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of cftr modulators
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
MX2020005753A
(es)
|
2017-12-08 |
2020-08-20 |
Vertex Pharma |
Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
ES2939775T3
(es)
|
2018-02-15 |
2023-04-26 |
Vertex Pharma |
Macrociclos como moduladores del regulador de la conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de los mismos, su uso en el tratamiento de la fibrosis quística, y procesos para elaborarlos
|
US20210009560A1
(en)
|
2018-03-30 |
2021-01-14 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of modulators of cftr
|
BR112021006392A2
(pt)
|
2018-10-05 |
2021-07-06 |
Vertex Pharma |
moduladores da alfa-1 antitripsina
|
DK3880197T3
(da)
|
2018-11-14 |
2023-03-27 |
Vertex Pharma |
Fremgangsmåder til behandling for cystisk fibrose
|
CA3121910A1
(en)
|
2018-12-17 |
2020-06-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
UY38630A
(es)
|
2019-04-03 |
2020-10-30 |
Vertex Pharma |
Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
UY38696A
(es)
|
2019-05-14 |
2020-11-30 |
Vertex Pharma |
Moduladores de alfa-1 antitripsina
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
AU2020328028A1
(en)
|
2019-08-14 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
CA3162219A1
(en)
|
2019-12-20 |
2021-06-24 |
Pasit Phiasivongsa |
Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
MX2023001744A
(es)
|
2020-08-13 |
2023-04-19 |
Vertex Pharma |
Formas cristalinas de moduladores de regulador de conductancia transmembrana de la fibrosis quística (cftr).
|
CA3202071A1
(en)
|
2020-11-17 |
2022-05-27 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
|
CA3204725A1
(en)
|
2020-12-10 |
2022-06-16 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
AU2022283934A1
(en)
|
2021-06-04 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
|
KR20240031300A
(ko)
|
2021-06-04 |
2024-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드
|
AU2022286438A1
(en)
|
2021-06-04 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
|
AU2022285758A1
(en)
|
2021-06-04 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran analogs as modulators of sodium channels
|
EP4347033A1
(en)
|
2021-06-04 |
2024-04-10 |
Vertex Pharmaceuticals Incorporated |
Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
|
WO2023150236A1
(en)
|
2022-02-03 |
2023-08-10 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
|
WO2023224924A1
(en)
|
2022-05-16 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a macrocyclic compounds as cftr modulators and their preparation
|
WO2023244562A1
(en)
|
2022-06-14 |
2023-12-21 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
WO2024031081A1
(en)
|
2022-08-04 |
2024-02-08 |
Vertex Pharmaceuticals Incorporated |
Compositions for the treatment of cftr-mediated diseases
|
WO2024054624A1
(en)
|
2022-09-09 |
2024-03-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of alpha-1 antitrypsin
|